8月15日,港交所官网显示,广州银诺医药集团股份有限公司(以下简称:银诺医药)成功登陆港交所,成为又一港股18A生物医药公司。中信证券、中金公司为其联席保荐人。值得注意的是,受到港交所生科板块回暖影响,银诺医药的打新非常火爆,超额认购到5364倍,比蜜雪的5200倍还高,认购资金盘3700亿。本次IPO中,银诺医药以18.68港元/股的发行价发行36,556,400股H股,按照发行价计算市值超85...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.